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Wilson’s disease (WD) is characterized by excessive accumulation of intracellular copper in
liver and extrahepatic tissues, leading to signiﬁcant oxidative stress and tissue damage. To
date, several diagnostic biomarkers for WD such as serum ceruloplasmin, serum or urine
copper levels and copper content in liver have been identiﬁed. However, these biomarkers
may not be convincing for the diagnosis in some WD patients. To identify additional novel
diagnostic biomarkers, we compared the serum protein proﬁles of asymptomatic childhood
WD patients (n520), without neurologic manifestation or liver cirrhosis, with normal
controls (n513). Fourteen spots, ﬁve up-regulated and nine down-regulated (42-fold), were
differentially expressed in WD patients in comparison to normal control on 2-DE. Among
them, three spots were down-regulated in both male and female WD. MS/MS analysis
revealed that the three spots were complement component C3, complement factor B and
alpha-2 macroglobulin. By comparative proteome analysis, complement component C3,
complement factor B and alpha-2 macroglobulin, which are related to oxidative stress and
inﬂammation, turned out to be good candidates for novel diagnostic biomarkers for early
stages of WD.
Keywords:
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1 Introduction
Copper, an essential trace element in living organisms, acts
as a cofactor for several enzymes due to its biologically
suitable redox potential. However, excess copper leads to
random oxidation of biomolecules with subsequent toxic
effects [1]. Wilson’s disease (WD) is an autosomal recessive
inherited copper metabolism disorder caused by mutation of
the ATP7B gene [2, 3]. The incidence of WD is estimated as
one in 30000 in most populations [4]. Alterations in the
ATP7B protein cause impaired copper efﬂux from the liver
into bile and decreased incorporation of copper into ceru-
loplasmin (CP), leading to its accumulation in the liver [5].
Manifestation of WD can be variable. It can be incidentally
detected in asymptomatic patients with abnormal liver
function alone, whereas symptomatic, early-stage patients
can be found with chronic liver disease, liver cirrhosis or
neurological impairment. The early diagnosis of WD is
important because it can be lethal when left untreated.
Patients with WD show decreased serum CP, increased
urinary excretion of copper, elevated hepatic copper
concentration and Kayser–Fleischer rings on cornea [6, 7].
Although serum CP, serum/urine copper levels and copper
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kers of WD, 5–40% of the patients with WD display normal
CP levels, and serum/urine copper levels may be equivocal
[8, 9]. In addition, invasive study is often required to evaluate
copper content in liver. Therefore, diagnosis can be inde-
terminate, especially in asymptomatic, early-stage patients.
This study was undertaken to ﬁnd novel biomarkers
of asymptomatic, early-stage WD. Using comparative
proteome analyses, including multiple afﬁnity removal
columns (MARC), 2-DE and MALDI-TOF, we identiﬁed the
differently expressed proteins and we discussed their func-
tional roles in asymptomatic WD patients.
2 Materials and methods
2.1 Serum sample preparation
Serum samples were collected from 20 asymptomatic
childhood WD patients, 12 males and 8 females, without
neurologic manifestation or liver cirrhosis. All of them were
detected by abnormal serum liver enzyme levels, which were
incidentally found during health screening or preoperative
examinations for minor surgical procedures not related to
WD, such as tonsillectomy. WD was diagnosed based on low
serum CP levels (o15mg/dL) and increased urinary copper
excretion (4100mg/day). Thirteen age- and sex-matched
individuals, six males and seven females, with normal liver
functions and CP levels were classiﬁed as normal group.
WD patients with same gender were randomly divided into
two groups, male WD patients (mWD1/2) and female WD
patients (fWD1/2), to give each group the same number of
patients (Table 1). Samples from normal group and
mWD1/2 and fWD1/2 were split into 300mL aliquots, frozen
and stored at 801C. The total protein content was deter-
mined using the Bradford method, according to the manu-
facturer’s instructions (Bio-Rad Laboratories, Hercules, CA,
USA). Written informed consent was obtained from each
individual, and the research protocol approved by the
Institutional Review Board (IRB) of Asan Medical Center,
University of Ulsan College of Medicine (Seoul, Korea).
2.2 Depletion of major abundant proteins using
MARC
Serum depletion was performed as described previously
[10]. The six most abundant proteins in each serum sample
were depleted using 4.6100mm MARC (Agilent,
Wilmington, DE, USA) with a binding capacity of 20mLo f
human serum. Chromatographic separation was
performed using a mobile phase reagent kit, according to
the standard LC protocol provided by the manufacturer.
Serum samples were diluted ﬁvefold with buffer A
containing protease inhibitors (COMPLETE
TM, Roche), and
ﬁltered through 0.22mm spin ﬁlters at 12000rpm for 1min
at room temperature. Flow-through MARC fractions were
pooled and precipitated with a precooled solution of 10%
trichloroacetic acid for 1h at 201C. Each precipitate was
washed with ice-cold acetone, and redissolved in sample
lysis buffer (7M urea, 2M thiourea, 100mM DTT, 4.5%
CHAPS and 40mM Tris).
2.3 2-DE
MARC-treated samples (800mg) were mixed with rehydra-
tion buffer (8M urea, 2% CHAPS, 65mM DTT, 0.5%
IPG buffer), according to the manufacturer’s instructions, to
a ﬁnal volume of 340mL, and applied onto immobilized pH
3–10NL strips (Amersham Biosciences, Uppsala, Sweden).
Isoelectric focusing was performed at 80000Vh. Strips
were applied to 12.5% polyacrylamide gels and electro-
phoresed until the dye reached end of the gel. After
protein ﬁxation for 1h, gels were stained with Coomassie
Brilliant Blue G250 for 24h, destained with H2O, scanned
in a Umax power Look 1100 (Umax data system)
and converted into electronic ﬁles, which were analyzed
with the Image Master Platinum 5.0 image analysis
program (Amersham Biosciences). Spot detection para-
meters were adjusted using a smooth by Algorithm. The
number of spots was automatically determined and
matched. The normalized volume was quantiﬁed as
percentage volume (%v), where %v5spot volume/
Table 1. Clinical data on control subjects and WD patients
Sex Group Number Age CP (mg/dL) Copper serum (ug/dL) AST(IU/L)
a) ALT(IU/L)
b)
mean (range) mean (7SD) mean (7SD) mean (7SD) mean (7SD)
Male Normal 6 9 (5–12) 33 (76.5) 115 (717.5) 35 (710) 25 (710)
mWD1
c) 6 9 (5–12) 2.2 (70.7) 13.4 (77.9) 279 (7228) 361 (7241)
mWD2 6 9 (6–12) 4.1 (72.0) 18.8 (79.9) 221 (7193) 260 (7224)
Female Normal 7 7 (5–12) 32 (75) 105 (717.5) 27.5 (76.3) 17.5 (78.8)
fWD1
d) 4 8 (5–12) 3.2 (70.7) 22.6 (717.6) 143 (784) 242 (7187)
fWD2 4 8 (6–10) 2.7 (70.4) 18.4 (78.6) 134 (767) 218 (7102)
a) Aspartate aminotransferase: GOT.
b) Alanine aminotransferase: GPT.
c) Male Wilson’s disease group.
d) Female Wilson’s disease group.
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than twofold were regarded as unique, representing differ-
entially expressed proteins.
2.4 Identiﬁcation of proteins using MS/MS
Protein spots were excised from CBB-stained gels, and
digested with trypsin (Promega, Madison, WI, USA). Tryptic
peptides were concentrated on POROS R2 and oligo R3
columns (Applied Biosystems, Foster City, CA, USA).
After washing each column with 70 and 100% ACN and
50mM ammonium bicarbonate, samples were applied to
the R2 and R3 columns, and eluted with CHCA (Sigma, St.
Louis, MO) dissolved in 70% ACN and 0.1% TFA
before MALDI-TOF analysis [11]. Mass spectra were
acquired on a 4700 Proteomics Analyzer (Applied Biosys-
tems) operated in the MS and MS/MS modes. The mass
spectrometer was set to acquire positive ion MS survey scans
over the mass range of 700–4000Da. The data were
processed to generate a list of precursor ions for interroga-
tion by MS/MS. Each raw spectrum was opened in Data
Explorer software and less than 40 top mass peaks
were selected by S/N threshold setting and then treated
with advanced base-line correction. The spectrum was cali-
brated with more than two peptides resulting from trypsin
autolysis (m/z 842.5100, 2211.1046). Peak list of mono-
isotopic masses was searched using the following para-
meters: trypsin as enzyme, one possible missed cleavage,
peptide tolerance of 0.5Da and mass tolerance of 100ppm.
Peptide mass ﬁngerprinting was performed using the
MASCOT search engine (http://matrixscience.com/) inclu-
ded in GPS Explorer software and ProFound program
(http://prowl.rockefeller.edu/). Mass spectra were used for
manual de novo sequencing, and sequences annotated with
Data Explorer software (Applied Biosystems). Peptide
matching and protein searches were performed using Swiss-
Prot and NCBI databases (ver.20061110, 4111659 sequences;
1417848065).
2.5 Western blot analysis
Serum proteins (30mg) were subjected to electrophoresis
on 10% SDS-polyacrylamide gels, and transferred to
PVDF membranes (Bio-Rad). After overnight blocking with
blocking buffer (TBS, 5% skimmed milk, 0.1% Tween 20),
membranes were incubated with polyclonal antibodies
against alpha-2 macroglobulin (a2M), complement compo-
nent C3 (C3), and complement factor B (FB) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), followed by HRP-
labeled secondary antibody. Blots were visualized using the
SuperSignal West Pico Chemiluminescent Substrate
(PIERCE, UK) detection system, according to the manu-
facturer’s instructions. An antibody against glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was employed as the
internal control.
2.6 Statistical analysis
All statistical analyses were performed using SPSS 12.0
software. Student’s t-test was applied to compare differences
between control subjects and WD patients.
Figure 1. Partial 2-DE comparison images
of normal subjects and asymptomatic WD
patients. Differentially expressed proteins
displaying 42-fold difference in levels are
indicated with numbered arrows.
Proteomics Clin. Appl. 2009, 3, 1185–1190 1187
& 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com3 Results
Serum protein proﬁles of mWD1/2, fWD1/2 and normal
individuals were analyzed using 2-DE, visualized by staining
with Coomassie Brilliant Blue G-250, and compared using the
Image Master Platinum 5.0 program (data not shown).
Comparing serum protein proﬁles between mWD1/2 and
fWD1/2 and normal control, ﬁve spots were up-regulated (spots
4–7 and 9) and nine down-regulated (spots 1–3, 8, and 10–14)
by at least twofold in depleted sera of asymptomatic WD
regard1ess of sex (Fig. 1). The selected spots were
re-analyzed using MALDI-TOF MS and subsequently
conﬁrmed by MS/MS (Table 2). Finally, spots 1, 2, 3, 8 and 11
were conﬁrmed to be down-regulated in both male and female
WD patients (Fig. 1 and Table 2). Spots 1 and 3, spot 2 and spot
11 were FB, C3 and a2M precursors, respectively. Western blot
analysis for C3, FB and a2M also showed decreased expressions
in WD patients (Fig. 2 and Supporting Information Fig. S1).
Following normalization in relation to GAPDH expression, C3,
FB and a2M levels were still decreased signiﬁcantly in the sera
of WD patients in comparison with those of normal subjects
(Fig. 2). a2M expression was decreased to 2.3-fold in male and
1.8-fold in female WD patients (po0.001), C3 to 1.8-fold in
male and 1.9 in female (po0.005) and FB to 2.4-fold in male
a n d1 . 6 - f o l di nf e m a l e( po0.005).
4 Discussion
In this study, three proteins, C3, FB and a2MG, were
differentially expressed in asymptomatic WD patients.
These proteins are known to be related with several func-
tions including inﬂammation, regulation of the cell cycle
and protection of cells against oxidative stress. C3 plays a
central role in activation of the classical and alternative
complement activation pathways [12], while FB is a crucial
component that regulates alternative complement pathway
[13, 14]. These proteins are synthesized primarily in the
liver, which is induced during acute inﬂammatory proces-
ses. Down-regulations of C3 and FB in WD imply reduced
activity of complement activation pathway in WD patients,
which may be caused by excessive consumption and/or
decreased synthesis due to hepatic copper toxicity.
a2M, a universal protease inhibitor and cytokine trans-
porter, is an evolutionarily conserved component of the
innate immune system [15, 16]. Moreover, a2M is a large
molecular-sized plasma protein produced by hepatocytes
[17] that is responsible for the inhibition and clearance of
proteases secreted by endogenous and exogenous pathogens
from the circulation [16]. Severe hepatocellular damage and
chronic liver disease lead to reduced production of the a2M
protein [18]. However, the WD patients enrolled in this
study did not have a severe hepatic damage but elevated
serum liver enzyme levels, which might lead to reduced
production. Therefore, reduced expression of a2M in
asymptomatic WD patients may indicate blunted acute
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toxicity.
Besides three proteins, which were down-regulated,
several proteins were differentially expressed in WD patients
to a lesser degree (Table 2). Nesprin, which was up-regu-
lated only in female WD, plays several fundamental roles
including maintenance of structural organization, regula-
tion of the cell cycle and maintaining/targeting protein
complexes common to the nuclear envelope and sarco-
plasmic reticulum, particularly in differentiated muscle cells
[19]. Elevation of nesprin-1 beta2 may reﬂect damage to the
cell membrane and cytoskeleton resulting from intracellular
copper accumulation. Peroxiredoxin 2 isoform b with down-
regulation in male WD is an intracellular antioxidant
protein that protects cells from oxidative stress through
redox regulation [20]. A reduction in the amount of perox-
iredoxin 2 isoform b may therefore suggest increased cell
susceptibility to oxidative damage induced by intracellular
copper accumulation [21]. Smad proteins mediate signaling
by members of the transforming growth factor-beta
superfamily [22]. Smurf1 is a member of the Hect domain
family of E3 ubiquitin ligases, which interacts with the
bone morphogenic protein (BMP) signaling proteins,
Smad1 and 5, the bone-speciﬁc transcription factor, Runx2/
Cbfa1, and type I BMP receptors mediating their degrada-
tion [23]. Additionally, Smurf1 possibly plays an important
role in osteoblast differentiation [24]. The relationship
between decreased expression of Smurf1 in female WD
and the pathogenetic effect on WD remains elusive, which is
needed to be investigated. Haptoglobin, a liver glycoprotein,
is primarily secreted by liver cells in response to a variety
of stimuli [25]. This hemoglobin-binding serum protein
participates in protection against heme-driven oxidative
stress [26]. Low haptoglobin levels are reported in various
clinical conditions, including tumor metastasis, severe
sepsis, hemolytic anemia and chronic liver disease [27, 28].
Moreover, haptoglobin has been reported as a potential
serum biomarker of ovarian cancers, [29, 30]. In our analy-
sis, haptoglobin precursor was down-regulated in female
WD (Table 2). In order to verify this result, we performed
Western blot analysis with the whole sera of WD
patients including male and female. The proportion of
haptogloblin was decreased in both male and female
WD compared with normal. However, haptogloblin of
female WD showed a little more down-regulated pattern
than male WD (Supporting Information Fig. S2). Profound
depletion of haptoglobin precursor may imply the presence
of asymptomatic hemolysis caused by copper toxicity
to red blood cells as well as reduced synthesis from the
damaged liver, but the reason for gender difference is yet to
be known.
In conclusion, our experiments indicate that C3, FB and
a2M are down-regulated in asymptomatic WD patients
implying impaired cellular response to inﬂammatory
stimulus, which might be caused by intracellular copper
accumulation in hepatic tissue. These proteins can be
candidates for novel diagnostic biomarkers for WD, parti-
cularly in the asymptomatic stage.
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